Lilly’s Alimta Brochure Does Not Include Specific Indication, Says DDMAC
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm pulled the patient brochure after receiving an untitled letter from FDA’s ad division.
You may also be interested in...
NICE Draft Negs Tarceva, Alimta For Treatment Of NSCLC
Neither Roche's erlotinib or Lilly's pemetrexed represent "good use of scarce" resources, NICE says in preliminary reports.
NICE Draft Negs Tarceva, Alimta For Treatment Of NSCLC
Neither Roche's erlotinib or Lilly's pemetrexed represent "good use of scarce" resources, NICE says in preliminary reports.
Alimta To Replace Taxotere As Standard For Non-Small Cell Lung Cancer – Lilly
Lilly expects its non-small cell lung cancer therapy Alimta (pemetrexed) to replace Taxotere (docetaxel) as the standard of care in the second-line setting, Exec VP-Pharmaceutical Operations John Lechleiter said Jan. 11 at the J.P. Morgan health care conference in San Francisco